Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6843 USD | -2.24% | +3.52% | -7.90% |
Evolution of the average Target Price on Cara Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Cara Therapeutics, Inc.
Canaccord Genuity | |
HC Wainwright | |
Needham & Co. | |
Piper Sandler | |
BofA Securities | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- CARA Stock
- Consensus Cara Therapeutics, Inc.